◀ Back to NPY6R

JAK2 — NPY6R

Text-mined interactions from Literome

Takeishi et al., J Mol Cell Cardiol 2001 (MAP Kinase Signaling System...) : PP2 ( 1 microm ) inhibited ischemia induced Src, BMK1 and JNK activation but not JAK2 and p38 activation
Tabet et al., J Hypertens 2005 : Non-receptor tyrosine kinases ( NRTK ) were studied using AG490 ( JAK2 inhibitor ) and PP2 ( Src inhibitor )
Li et al., J Biol Chem 2008 : PP2 , a Fyn-specific inhibitor, blocked JAK2 , STAT3, and p38 MAPK activation and significantly attenuated apoptosis induced by H ( 2 ) O ( 2 )
Wu et al., Br J Pharmacol 2009 : Effects of tripterine were investigated on endothelial barrier function, inducible nitric oxide synthase (iNOS) expression, nicotinamide adenine dinucleotide phasphate ( NADPH ) oxidase activity, 3-nitrotyrosine formation, protein phosphatase type 2A (PP2A) activity, activation of extracellular regulated kinase (ERK), c-Jun terminal kinase (JNK) and Janus kinase ( Jak2 ), and degradation of IkappaB in microvascular endothelial cells exposed to pro-inflammatory stimulus [ lipopolysaccharide (LPS) + interferon gamma (IFNgamma) ] and on vascular permeability in air pouches of mice injected with LPS + IFNgamma
Lin et al., Toxicol In Vitro 2010 (Breast Neoplasms) : Moreover, the JAK2 inhibitor AG490 blocked JAK2, STAT3, Src, PI3K, and Akt activation, whereas both Src inhibitor PP2 and PI3K inhibitor wortmannin did not affect JAK2 activation